Breaking Finance News

CRH Medical (TSE:CRH) target price dropped to $10.50, released a report today by TD Securities

Having a price of $7.00, CRH Medical (TSE:CRH) traded -0.32% lower on the day. With the last close down -62.66% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the same period. CRH Medical has recorded a 50-day average of $5.28 and a two hundred day average of $8.22. Volume of trade was down over the average, with 425,747 shares of CRH changing hands under the typical 511,587

In a report released on 07/07/2017 TD Securities reduced the stock price target of CRH Medical (TSE:CRH) from $12.00 to $10.50 indicating a possible upside of 0.50%.

On 4/28/2017, TD Securities released a statement on CRH Medical (TSE:CRH) bumped up the target price from $0.00 to $12.00 that suggested an upside of 0.49%.

Recent Performance Chart

CRH Medical (TSE:CRH)

CRH Medical has a 52 week low of $2.67 and a 52 week high of $12.35 with a P/E ratio of 31.33 The company’s market cap is currently $0.

Also covering CRH Medical's stock price target, a total of 7 brokerages have issued a ratings update on the company. The average stock price target is $5.99 with three analysts rating the stock a strong buy, 4 brokers rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 firms rating the stock a sell.

About CRH Medical (TSE:CRH)

CRH Medical Corporation is a Canada-based healthcare products and services company. The Company focused on providing physicians with services and products for the treatment of gastrointestinal diseases. The Company also provides anesthesiology services to gastroenterologists in the United States through its subsidiaries. The Company specializes in the treatment of hemorrhoids utilizing its treatment protocol and technology. The Company's product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company's CRH O'Regan System, platform that provides gastrointestinal is a single use, disposable, hemorrhoid banding technology for treating hemorrhoid grades I-IV. The Company distributes the CRH O'Regan System, treatment protocols, operational and marketing expertise as a package to physicians. The Company's subsidiary, Gastroenterology Anesthesia Associates, LLC, provides anesthesiology services for gastroenterology procedures.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *